Printed From BioPortfolio.com
Versartis’ phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
03:01 EDT 25 Sep 2017 | Pharmaceutical Business Review
Versartis, an endocrine-focused biopharmaceutical firm that is developing somavaratan, a novel,aong-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that the Velocity Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (GHD) did not meet its primary endpoint of non-inferiority.
Original Article: Versartis’ phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
